Bevatas 400 Solution for Infusion
Marketer
Intas Pharmaceuticals Ltd
Salt Composition
Bevacizumab (400mg)
Overview Bevatas 400 Solution for Infusion
Oncaspar 400mg intravenous solution is an anti-neoplastic agent indicated in the management of colorectal, non-small cell lung, renal cell, and ovarian cancers, as well as brain tumors and cervical cancer. Its mechanism of action involves angiogenesis inhibition, thus hindering tumor growth. Oncaspar 400mg is a valuable first-line treatment option when administered concurrently with other chemotherapeutic agents, delivered intravenously via a peripheral vein or implanted port. Dosage and treatment length are determined by your oncologist, who will also monitor for infusion-related adverse events such as hypertension and respiratory distress. Therapy continues as long as disease control is maintained and side effects are tolerable, with discontinuation determined by your physician. Regular monitoring of blood pressure and urinary protein levels may be advised. Commonly reported side effects include rectal hemorrhage, altered taste perception, and cephalalgia. Pre-surgical notification of Oncaspar 400mg use is crucial due to its potential to impair wound healing. Increased bleeding risk necessitates prompt medical attention for any unusual hemorrhaging. Disclose current pregnancies, pregnancy intentions, or breastfeeding status to your physician. Comprehensive disclosure of all concomitant medications is essential, as significant drug interactions are possible.
Primary Ingredients of Bevatas 400 Solution for Infusion
No text provided. Please provide the text you wish me to rephrase.
Uses of Bevatas 400 Solution for Infusion
Colorectal cancer, ovarian neoplasm, cervical carcinoma, renal cell carcinoma, brain cancer, and non-small cell lung carcinoma.
Major Benefits of Bevatas 400 Solution for Infusion:
This medication will be administered by your healthcare provider. Self-medication is strongly discouraged.
Common Side effects of Bevatas 400 Solution for Infusion:
- Exfoliative dermatitis
- High blood pressure
- Nosebleeds
- Protein in urine
- Decreased appetite
- Electrolyte imbalance
- Peripheral sensory neuropathy
- Breathlessness
- Thromboembolism
- Wound healing complications
- Ovarian failure
- Decreased white blood cell count (lymphocytes)
- Low blood platelets
- Mucosal inflammation
- Abscess
- Cellulitis
- Hypersensitivity
- Rectovaginal fistula
How to use Bevatas 400 Solution for Infusion:
This medication will be administered by your healthcare provider. Self-medication is not advised.
How Bevatas 400 Solution for Infusion works:
Bevatas 400 Infusion Solution is an anti-angiogenesis drug. Its mechanism of action involves inhibiting vascular endothelial growth factor (VEGF), a protein crucial for blood vessel development. This consequently restricts the supply of oxygen and nutrients to tumor cells.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Bevatas 400 Solution for Infusion hasn't been established as safe. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
The use of Bevatas 400 Infusion Solution during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the advantages against possible risks prior to prescribing. Physician consultation is advised.
Breast feedingCONSULT YOUR DOCTOR
Infusion solution Bevatas 400 is likely unsafe for breastfeeding mothers. Available human data indicate potential drug transfer to breast milk, posing a possible risk to the infant.
DrivingUNSAFE
Bevatas 400 Infusion may induce adverse reactions that could compromise driving safety. Reported side effects include drowsiness and loss of consciousness, potentially impacting driving capabilities.
KidneySAFE IF PRESCRIBED
The intravenous Bevatas 400 solution is likely safe for individuals with impaired renal function. Preliminary evidence indicates dose modification may be unnecessary for this patient population. Physician consultation is recommended.
LiverSAFE IF PRESCRIBED
Bevatas 400 intravenous solution appears to pose minimal risk for individuals with hepatic impairment. Available evidence indicates that dose modification of Bevatas 400 intravenous solution might be unnecessary in this population. Physician consultation is advised.
What if you forget to take Bevatas 400 Solution for Infusion :
Should you forget a Bevatas 400 Infusion Solution dose, seek your physician's advice.
Facts to Know About Bevatas 400 Solution for Infusion
| Label | Value |
|---|---|
| Chemical Type | Monoclonal antibody |
| Developing Habits | No. |
| Treatment Category | Cancer Treatments |
| Action Category | VEGF inhibitor |
3,018 People bought this recently